Skip to content

Clinical study of midapril hydrochloride combined with hydrochlorothiazide in the treatment of essential hypertension

Clinical study of midapril hydrochloride combined with hydrochlorothiazide in the treatment of essential hypertension

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089563
Enrollment
Unknown
Registered
2024-09-11
Start date
2024-09-15
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

Control group:Oral hydrochlorothiazide
Experimental group:Oral hydrochlorothiazide + imidapril hydrochloride

Sponsors

Jiangyou Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) The subjects voluntarily agree to participate in the study and sign a written informed consent; (2) Age 18-75 years old, male or female; (3) Clinically diagnosed as hypertensive patients, meeting the diagnostic criteria for hypertension [systolic blood pressure = 140mmHg, and/or diastolic blood pressure =90 mmHg]; (4) Not taking antihypertensive drugs in the past 2 weeks or stopping the original antihypertensive drugs for more than 2 weeks.

Exclusion criteria

Exclusion criteria: (1) Those who have a history of allergy or contraindications to the investigational drugs and excipients; (2) A history of severe liver and kidney disease; (3) Patients with severe cerebrovascular disease within 6 months before enrollment; (4) Patients with respiratory cough (bronchitis, COPD, etc.) and throat discomfort; (5) Pregnant and lactating women; (6) Suspected or confirmed secondary hypertension; (7) The researcher thinks that it is not suitable to participate in this researcher.

Design outcomes

Primary

MeasureTime frame
Antihypertensive efficiency;

Secondary

MeasureTime frame
Dry cough;

Countries

China

Contacts

Public ContactHong Le

Jiangyou Second People's Hospital

754746206@qq.com+86 137 0830 2754

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026